Tests a cognitive battery that separates word-meaning problems from thinking-control problems

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for French-speaking adults aged 50 to 90, either without memory or thinking problems or with Alzheimer's disease, vascular cognitive impairment or semantic variant primary progressive aphasia.

Age

50 to 90 years (inclusive)

Sex

All sexes

Disease stage

People with cognitive impairment need Alzheimer's disease (minor or major stage), vascular neurocognitive impairment, or the semantic variant of primary progressive aphasia. Other participants have no cognitive impairment.

Earlier treatment

People with cognitive impairment must be receiving memory care.

Biomarker or test result

People with cognitive impairment need an MMSE score of 20/30 or more within the 6 months before enrollment.

Main reasons for not taking part

• Severe, progressive or unstable medical conditions that may interfere with the tests (epilepsy, acute psychiatric or psychotic disorders, visual hallucinations, acute infection)
• Substance use that may affect thinking performance
• Deafness or blindness that may affect the tests
• People under guardianship, curatorship or legal protection
• Pregnant, postpartum or breastfeeding women

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 50 and 90 years old?YesNo

What the trial wants to find out

This protocol describes a study aimed at evaluating the psychometric properties of the ExéSem battery, developed to differentiate semantic deficits from executive semantic impairments in patients with post-lesional or neurodegenerative anomia. Currently available tools do not allow a straightforward distinction between these deficits, limiting diagnostic accuracy and clinical management. The ExéSem battery was developed through a collaboration between Hospices Civils de Lyon, the University of Mons, and Laval University to address this gap.

The 2 groups in the trial

• Participants without cognitive impairment

  Participanst with a MoCA score greater than or equal to 26/30 and a score greater than the alert threshold based on age and education level on the DTLA scale. Participants who have never received a diagnosis of cognitive impairment.

  Treatment: ExéSem cognitive battery

• Participants with Cognitive Impairment

  Participants receiving memory clinic care with a diagnosis of Alzheimer's disease, at the stage of minor or major neurocognitive impairment, according to the 2011 NIA-AA criteria, or with a diagnosis of vascular neurocognitive impairment according to the VasCog-2-WSO diagnostic criteria , or with a diagnosis of primary progressive aphasia with semantic variant. Participants with a Mini-Mental State Examination (MMSE) score ≥ 20/30, within the 6 months preceding enrollment;

  Treatment: ExéSem cognitive battery